A phase II clinical trial was planned based on optimal two-stage Simon's design. Eligibility criteria included patients with an Eastern Cooperative Oncology Group (ECOG) performance status of ≤3. The primary endpoint was to evaluate the symptoms response rate produced by a radiotherapy regimen based on the delivery of 4 radiotherapy fractions (5 Gy per fraction) with a twice daily fractionation in two consecutive days.
Results:
Twenty-nine patients were enrolled in this trial. Characteristics of the patients were: male/female: 16/13; median age: 66 years (range: 46-87). ECOG performance status was <3 in 25 patients (86.2%). With a median follow-up time of 5.0 months (range, 1 to 36 months), 9 G1-2 gastrointestinal (31%), 2 G1 haematological (6.8%) and 6 G1 skin (20.7%) toxicities were recorded. Only 1 patient (3.4%) experienced G3 acute gastro-intestinal toxicity. Of 29 symptomatic patients, 27 showed an improvement or resolution of baseline symptoms (overall palliative response rate: 92.6%). Three-month overall survival was 92.2% (median survival time: not reached). In 25 patients with pain, a significant reduction of this symptom was recorded in terms of Drug Score (mean baseline Drug Score vs mean Drug Score at follow-up: 5.3 vs 4.0; p=0.04).
Conclusion: Short-course accelerated radiotherapy on complicated bone metastases (20 Gy in twice daily fractions for 2 consecutive days) is tolerated and effective in terms of symptom relief. A phase III comparison against a standard palliative regimen (30 Gy in 10 fractions) has been planned in this patient population. Purpose or Objective: More than 90% of patients with metastatic castration resistant prostate cancer (CRPC) have radiologic evidence of bone metastases. Radium-223 dichloride therapy showed improved overall survival, quality of life and symptom control in patients with symptomatic bone metastases. Aim of the present study is to evaluate clinical course of patients treated in our centre including biochemical and imaging response.
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Material and Methods:
Since November 2014 we started the treatment of symptomatic bone metastatic CRPC patients with Radium-223 dichloride (50kBq/kg, every 4 weeks). Before and after every administration the following parameter were recorded: PSA and alkaline phosphatase (ALP) values, pain numerical rating scale (NRS), performance status (ECOG scale), analgesic therapy and side effects (graded according to the CTCAE v. 4 classification). A whole body scintigraphy was performed before and one month after the treatment.
Results: Twenty patients (total: 70 administrations) were treated. All patients showed increased PSA value and reduced ALP values. Performance status, evaluated with ECOG scale, was improved in all patients. Pain control was excellent, with reduction of NRS and analgesic therapies in all patients. Most patients showed only G1 toxicity: anaemia (15 pts), fatigue (3 pts), diarrhea (1 pt), nausea (1 pt), and pain flare-up (6 pts).
Eight patients completed the 6 planned cycles of therapy. Six patients discontinued treatment due to adverse events: anaemia (2 pts), pathological fracture of the femur (1 pt), severe bleeding (2 pts) and complications in uncontrolled diabetes (1 pt). The other patients are still under treatment. Whole body scintigraphy performed one month after the end of the treatment demonstrated in all patients a reduced intensity and number of uptake areas without correlation with PSA values.
Conclusion: Treatment with Radium 223 in patients with CRPC and symptomatic bone metastases was tolerated in the majority of patients. High response rates in terms of symptom control and QoL improvement were recorded.
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